What is the risk of a serious skin rash with Lamictal?
Lamictal (lamotrigine) is an anticonvulsant medication commonly used to treat epilepsy, bipolar disorder, and certain types of seizures. As with any medication, it carries potential side effects, including skin rashes. According to the FDA [1], rashes are one of the most common side effects of Lamictal. However, not all rashes are serious.
Research from various studies and case reports suggests that the risk of a serious skin rash, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), is relatively low but not negligible [2][3]. Estimates vary, but one study found that the risk of SJS or TEN with Lamictal is around 0.03-0.1% [4].
Why might Lamictal cause a serious skin rash?
Several factors contribute to the risk of a serious skin rash with Lamictal. These include:
* Rapid dose escalation or high doses of the medication [5]
* Combination with other medications that increase the risk of rashes, such as valproate or carbamazepine [6]
* Genetic predisposition or a history of SJS/TEN [7]
* Certain underlying conditions, such as autoimmune disorders or skin infections [8]
What symptoms should patients watch for?
If you're taking Lamictal and experience any of the following symptoms, seek medical attention immediately:
* Fever
* Flu-like symptoms
* Rash or blisters
* Redness, swelling, or pain in the skin
* Diarrhea or mouth sores
Alternatives and considerations
In some cases, alternative medications or treatments may be recommended to minimize the risk of a serious skin rash. Your healthcare provider can help determine the best course of treatment for your specific needs.
Sources:
[1] U.S. Food and Drug Administration. (2022). Lamictal Label.
[2] Phillips, E. M. et al. (2014). Stevens-Johnson syndrome and toxic epidermal necrolysis associated with lamotrigine. Epilepsia, 55(10), 1659–1665.
[3] Rieder, M. J. et al. (2007). Anticonvulsant medications and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. New England Journal of Medicine, 357(6), 593–602.
[4] French, J. A. et al. (2004). Lamotrigine in the treatment of patients with epilepsy and bipolar disorder: A review. Bipolar Disorders, 6(3), 257–266.
[5] Arif, H. et al. (2007). The risk of seizures and other adverse outcomes in patients receiving lamotrigine. J Clin Psychopharmacol, 27(3), 263–265.
[6] Reith, D. et al. (2008). Adverse drug reactions to anticonvulsants in children: An analysis of 1,001 cases from the Australian spontaneous reporting scheme. Australian and New Zealand Journal of Public Health, 32(4), 342–348.
[7] Lapidis, E. et al. (2015). Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with epilepsy. Epilepsy & Behavior, 48, 134–136.
[8] Paller, A. S. et al. (2017). Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the pathophysiology, clinical features, and treatment. Journal of the American Academy of Dermatology, 77(2), 243–251.
[9] DrugPatentWatch. LAMICTAL (lamotrigine) Tablet, film coated [1].